Compare Lamb Weston Holdings Inc (LW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Sana Biotechnology Inc — how do they compare? Lamb Weston Holdings Inc trades at $49.3 (market cap $6.53B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Lamb Weston Holdings Inc is far larger — about 7.4× Sana Biotechnology Inc's market cap, and Lamb Weston Holdings Inc pays a 3.22% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| LW | SANA | |
|---|---|---|
Market Cap | $6.53B | $879.40M |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $5.92 |
52-Week Low | $38.48 | $2.68 |
Enterprise Value | $10.49B | $853.59M |
Dividend Yield | 3.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
